Presentation (CTI)

OBJECTIVES: Background: Treatment with allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancy causes a high relapsing rate. T cells engineered to express T cell receptors (TCR; TCR-T) specific for hematopoietic-limited minor histocompatibility (H) antigens may provide potent effects post-treatment of HSCT. The research aimed to evaluate the effect of HSCT after post-treatment of car T cell administration in hematologic cancer patient
METHODS: The literature search was conducted in Medline/PubMed, Embase, Scopus Cochrane, and Google Scholar to identify the original studies that reported patients in complete remission (CR) following CAR-T cell therapy in favor of or against HSCT. Two independent reviewers were involved in all the steps of the review. All the statistical analysis was performed in R version 4.3 2 and p < 0.05 was considered statistically significant.
RESULTS: A total 23 studies with 1589 patients were included in the meta-analysis. Our findings revealed lower relapse rate (RR: 0.51, 95% CI: 0.38-0.63, P = 0.003), increased overall survival (HR: 0.49, 95% CI: 0.37-0.61, P = 0.0001) and improved disease-free survival (HR: 0.25, 95% CI: 0.12-0.48, P = 0.0001) with post-HSCT after CAR-T cell therapy.
CONCLUSIONS: Overall post-HSCT after CAR-T cell therapy, lowered the relapse rate and improved the long-term survival of hematologic malignant patients. After CAR-T therapy, all patients would benefit from post-HSCT.